- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Daniel Petrylak Explains PD-1, PD-L1 Expression in Bladder Cancer Treatment
New study results being presented at the American Society of Clinical Oncology's annual meeting in Chicago found that the PD-1 and PD-L1 biomarkers can be used to determine response and resistance, explained Daniel P. Petrylak, MD.
New study results being presented at the American Society of Clinical Oncology's annual meeting in Chicago found that the PD-1 and PD-L1 biomarkers can be used to determine response and resistance, explained Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology at the Yale Cancer Center. He will be presenting the results of a trial on PD-1 and PD-L1 expression in bladder cancer.
"We need to diligently assess tissue in these patients to help understand the marker pattern and how it can be used to treat them," he said.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
